BUILT WITH GUIDANCE FROM LEADING CLINICIANS & EXPERTS
Leading Clinicians from around the country have donated their time to help Believe Limited grasp and translate some of the most important scientific concepts in our community into tactile learning opportunities for young people and families. With their guidance we’ve built the first-of-its-kind, hands-on community Science Fair, bringing education and engagement to NHF BDC 2019. Meet our Scientific Advisors below.
DR. MICHAEL WANG, MD
Dr. Michael Wang is a pediatric hematologist-oncologist in Aurora, Colorado and is affiliated with multiple hospitals in the area, including Children's Hospital Colorado and UCHealth University of Colorado Hospital. He is the Clinical Director for the Hemophilia Treatment Center in Denver, CO. He received his medical degree from the University of Rochester School of Medicine and Dentistry and has been in practice for more than 20 years. Dr. Wang is dedicated to advancing clinical coagulation, by leading a multidisciplinary team that focuses our advancing knowledge and innovation in caring for patients with bleeding and clotting disorders. He believes by combining clinical care, health care delivery improvement, patient engagement, clinical trials, and teaching, we aim to improve the lives of our patients throughout their entire lifespan.
BRENDAN HAYES
Brendan Hayes is the Director of External Affairs at the National Hemophilia Foundation and leads NHF’s Gene Therapy Initiative which includes developing accurate, non-biased educational content on gene therapy, working with payers and policymakers to ensure patients have access to these groundbreaking therapies, and strengthening collaborations with national rare disease and patient advocacy organizations.
DR. DORIS QUON, MD
Doris V. Quon, MD, PhD is board-certified in Hematology and Internal Medicine She obtained her Ph.D. in Microbiology & Immunotherapy as well as her M.D. at the UCLA School of Medicine, and did her Residency in Internal Medicine and Fellowship in Hematology-Oncology at Medical Center at UCLA. Dr. Quon first began at the Hemophilia Treatment Center at Orthopaedic Hospital in 2003 where, within a few years, she was appointed Associate Director, followed by the position of Director of the Hemophilia Treatment Center in 2009. Dr. Quon is the Associate Medical Director at the Sarcoma Oncology Center. She has an active role in coordinating the federally funded (Western States/Region IX) Hemophilia activities of the center and is the current Medical Director of the Hemophilia Foundation of Southern California. Dr. Quon has published numerous papers and has been the Principal Investigator of clinical trial studies including hemophilia gene therapy, in addition to receiving numerous awards and honors including ASCO Young Investigator Award, AOA Medical Student Research Award and Alumni Association Graduate Student Distinguished Scholar Award.
DR. STEVEN PIPE, MD
Dr. Steven Pipe is Associate Professor, Coagulation, Director, Coagulation Laboratory, and Laurence A. Boxer, MD Research Professor of Pediatrics and Communicable Diseases in the Department of Pathology, Michigan Medicine, at the University of Michigan. Dr. Pipe is also National Hemophilia Foundation MASAC Chair. Dr. Pipe completed his undergraduate medical training at the University of Toronto, and his pediatric training at McMaster University in Hamilton, Ontario. He came to the University of Michigan in 1993 and completed his pediatric hematology and oncology training in 1996. Dr. Pipe is an Associate Professor of Pediatrics and Pathology and currently serves as Director of the Division of Pediatric Hematology and Oncology, Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program and Director of the Special Coagulation Laboratory. His clinical interests include both bleeding and thrombotic disorders as well as congenital vascular anomalies. Dr. Pipe also directs a basic research lab investigating coagulation factor VIII and molecular mechanisms of hemophilia A.
DR. CHRISTOPHER WALSH, MD, PhD
Christopher E. Walsh, MD, PhD, is Associate Professor and Director of the Hemophilia Program in the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai in New York City. He received his PhD in Biochemistry from Wake Forest School of Medicine and his MD from Tulane University School of Medicine. He then completed an internship and a residency in Internal Medicine at North Carolina Memorial Hospital in Chapel Hill and a residency in Internal Medicine and a fellowship in Hematology at the National Institutes of Health in Bethesda, Maryland. Dr. Walsh is board-certified in Hematology and Internal Medicine.
Dr. Walsh is the Regional Director of ATHN funded HTCs in New England. He sits on the boards of NHF MASAC, American Thrombosis and Hemostasis Network (ATHN), Hemophilia Federation of America and Hemophilia of New York. His basic research focuses on gene therapy of blood diseases. He pioneered the research into Adeno-associated virus and its first use as a gene therapy vector. He is also actively developing gene therapies for hemophilia A and B, von Willebrand disease, and other disorders.
DR. CINDY BAILEY, PT, PhD
Cindy Bailey is a past Assistant Professor of Clinical Practice in the Dept. of Biokinesiology & Physical Therapy at the University of Southern California (USC) & is currently Clinical Faculty at Mount Saint Mary's Physical Therapy Doctorate program. She is the Director of P.T./O.T. at Los Angeles Orthopaedic Institute for Children (OIC) and the Physical Therapist for the Orthopaedic Hemophilia Treatment Center. She is also an administrator for OIC Sports Care Outreach program. Dr. Bailey's post graduate work has included an Advanced Residency at Kaiser West Los Angeles (KWLA) in Manual Orthopaedic Physical Therapy & a Fellowship at USC Keck School of Medicine in Medical Education Teaching & Learning. Since 1997, Dr. Bailey has worked and traveled with the USC ice hockey team as their Certified Athletic Trainer and EMT & has been invited as coverage for Olympics, Pan Am and Goodwill games as well as World Championships. Dr. Bailey has been a world leader in Kinesiology Taping education and practice. Her new interest and research area is in Musculoskeletal Ultrasound with orthopedics and the hemophilic patients.
DR. GLENN PIERCE, MD
Dr. Glenn Pierce is currently an independent consultant, entrepreneur-in-residence at Third Rock Ventures and serves on the World Federation of Hemophilia (WFH) and WFHUSA Board of Directors and the National Hemophilia Foundation (NHF) (US) Medical and Scientific Advisory Council. Glenn is also a director of Voyager Therapeutics and Global Blood Therapeutics, two publicly held biotechnology companies.
Glenn retired from Biogen in 2014 as senior vice president of Hematology, Cell and Gene Therapies. Dr. Pierce has 30 years’ experience in biotechnology research and development. He received an M.D. and a Ph.D. in Immunology, both from Case Western Reserve University in Cleveland, Ohio and did his postgraduate training in pathology and hematology research at Washington University in St. Louis, Missouri.
DR. MICHAEL TARANTINO, MD
Dr. Tarantino has 25 years of experience in hematology, with seven years as the Founder, Medical Director and President of the Bleeding & Clotting Disorders Institute. For over two decades he has devoted his medical career to the management of bleeding and clotting disorders, as well as non-malignant hematology disorders. Dr. Tarantino also serves as the medical director of the Anticoagulation Consultation Service at St. Francis Medical Center and co- chairs the Anti-thrombosis subcommittee. Since 2008, Dr. Tarantino is also a tenured Professor of Pediatrics and Medicine at the University Of Illinois College Of Medicine in Peoria and is active in teaching medical students, residents and allied health professionals.
Dr. Tarantino earned a Doctor of Medicine degree from the University of Wisconsin School of Medicine and Public Health in 1987. He then completed a residency in pediatrics from the University of Arizona in 1990 and a fellowship in pediatric hematology and oncology from the University of Wisconsin in 1993.
He is board certified in Pediatric Hematology and Oncology. He is a longstanding member of the Medical and Scientific Advisory Council of the National Hemophilia Foundation and a member of the Medical Advisory Board of the Platelet Disorder Association. Dr. Tarantino has served on numerous Boards of Directors, Advisory Boards and Steering Committees including those of the Hemophilia Foundation of Illinois, the acclaimed SIPPET study, and the ATHN 2 study. In 2012 and 2014, he received a Patient's Choice Award from Vitals, and he was honored as a physician of the year by the National Hemophilia Foundation from 2012-2013. He was named as one of America's Top Doctors by Castle Connolly from 2012-2013, and as a Compassionate Doctor from Vitals in 2012. In 2014 the University Of Illinois College Of Medicine presented him with an Alpha Omega Alpha Teaching Award.
Dr. Tarantino has authored or co-authored over 100 peer-reviewed papers, reviews, and book chapters and over 125 scientific abstracts.
